CL2023000121A1 - Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas - Google Patents

Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas

Info

Publication number
CL2023000121A1
CL2023000121A1 CL2023000121A CL2023000121A CL2023000121A1 CL 2023000121 A1 CL2023000121 A1 CL 2023000121A1 CL 2023000121 A CL2023000121 A CL 2023000121A CL 2023000121 A CL2023000121 A CL 2023000121A CL 2023000121 A1 CL2023000121 A1 CL 2023000121A1
Authority
CL
Chile
Prior art keywords
antibodies
treatment
neutrophilic dermatoses
neutrophilic
present
Prior art date
Application number
CL2023000121A
Other languages
English (en)
Inventor
Fine Jay
Lamar Janine
John Padula Steven
Ramanujam Meera
Visvanathan Sudha
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2023000121A1 publication Critical patent/CL2023000121A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar, prevenir o mejorar una dermatosis neutrófila. Los métodos de la presente invención incluyen administrar a un paciente que tiene una dermatosis neutrófila una composición farmacéutica que incluye un anticuerpo contra el receptor de interleucina 36 (anti-IL-36R).
CL2023000121A 2020-07-17 2023-01-12 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas CL2023000121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063053129P 2020-07-17 2020-07-17

Publications (1)

Publication Number Publication Date
CL2023000121A1 true CL2023000121A1 (es) 2023-09-08

Family

ID=77265246

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000121A CL2023000121A1 (es) 2020-07-17 2023-01-12 Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas

Country Status (12)

Country Link
US (2) US12098207B2 (es)
EP (1) EP4182022A1 (es)
JP (1) JP7812364B2 (es)
KR (1) KR20230038774A (es)
CN (1) CN116745315A (es)
AU (1) AU2021309957A1 (es)
BR (1) BR112022026999A2 (es)
CA (1) CA3188382A1 (es)
CL (1) CL2023000121A1 (es)
MX (1) MX2023000763A (es)
TW (1) TW202225190A (es)
WO (1) WO2022015920A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
WO2022150642A1 (en) * 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CN120835899A (zh) * 2023-03-09 2025-10-24 勃林格殷格翰国际有限公司 抗il-36r抗体用于治疗化脓性汗腺炎（hs）的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
PT1003861E (pt) 1997-08-01 2007-01-31 Schering Corp Proteínas de membrana de células de mamíferos;reagentes relacionados
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
CA2499891A1 (en) 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090270480A1 (en) 2005-12-28 2009-10-29 Bernard Amegadzie Markers and Methods for Assessing and Treating Psoriasis and Related Disorders
CA2662549C (en) 2006-09-08 2014-10-28 Amgen Inc. Il-1 family variants
WO2008133857A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
BRPI0813966A8 (pt) 2007-06-29 2016-02-10 Schering Corp Usos de mdl-1
KR20110048536A (ko) 2008-08-28 2011-05-11 와이어쓰 엘엘씨 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
CA2801917C (en) 2010-06-03 2017-04-25 Abbvie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
RS67639B1 (sr) 2011-11-16 2026-02-27 Boehringer Ingelheim Int Anti il-36r antitela
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
EP4223312A1 (en) 2013-08-15 2023-08-09 Novartis AG Methods of treating plaque psoriasis using il-17 antagonists
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
RU2745898C2 (ru) * 2015-04-15 2021-04-02 Анаптисбайо, Инк. Антитела, направленные против рецептора интерлейкина 36 (il-36r)
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
US20180273627A1 (en) 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL280013B2 (en) 2018-07-16 2026-05-01 Regeneron Pharmaceuticals Inc Anti-IL36R antibodies
IL315703A (en) * 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
US11884719B2 (en) * 2018-12-21 2024-01-30 23Andme, Inc. Anti-IL-36 antibodies and methods of use thereof
TW202037604A (zh) 2018-12-27 2020-10-16 德商百靈佳殷格翰國際股份有限公司 治療掌蹠膿疱症之抗il-36r抗體
EA202192405A1 (ru) 2019-03-08 2022-01-13 Бёрингер Ингельхайм Интернациональ Гмбх Составы антител против il-36r
WO2021087245A1 (en) 2019-10-30 2021-05-06 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
KR20240004718A (ko) * 2021-05-03 2024-01-11 베링거 인겔하임 인터내셔날 게엠베하 스페솔리맙의 제조방법

Also Published As

Publication number Publication date
JP7812364B2 (ja) 2026-02-09
AU2021309957A1 (en) 2023-02-02
BR112022026999A2 (pt) 2023-01-24
TW202225190A (zh) 2022-07-01
CA3188382A1 (en) 2022-01-20
US20220073628A1 (en) 2022-03-10
WO2022015920A1 (en) 2022-01-20
KR20230038774A (ko) 2023-03-21
JP2023534955A (ja) 2023-08-15
CN116745315A (zh) 2023-09-12
EP4182022A1 (en) 2023-05-24
US20240392019A1 (en) 2024-11-28
MX2023000763A (es) 2023-02-13
US12098207B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
MX2024007358A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
PA8807801A1 (es) Inhibidores de cinesina como productos terapeuticos para el cancer
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
MX2019012032A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2020002465A1 (es) Método de tratamiento de enfermedad fibrótica
CL2025003481A1 (es) Anticuerpos anti-cd20 y estructuras car-t
BR112022020643A2 (pt) Método de tratamento de esteato-hepatite não alcoólica
CL2022002829A1 (es) Anticuerpo anti-ox40 y usos del mismo
CL2022000091A1 (es) Métodos para tratar la pancreatitis. (divisional de solicitud n° 202100585)
BR112023026992A2 (pt) Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
ECSP23076276A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2022005245A (es) Regimen de dosificacion de anticuerpos anti-cd27 para el tratamiento de cancer.
MX2023005032A (es) Anticuerpos para tratamientos con opioides.
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2024015160A (es) Metodos para el tratamiento de afecciones de perdida de sangre